Boehringer Ingelheim: ESOC 2019 – How NOAC Selection and Reversal can help Protect our Patients: Your Questions Answered

1) Keeping pace with advances in anticoagulation – Stephen Davis, Australia

2) What is the evidence for dabigatran? – Richard A. Bernstein, USA

3) What is the evidence for NOAC reversal strategies? – Sheila Martins, Brazil

4 How do we manage dabigatran and idarucizumab in neurological emergencies – Martin Grond, Germany

LEAVE YOUR COMMENT

Your email address will not be published.